Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **combination otic suspension** containing four active ingredients: **neomycin sulfate** (an aminoglycoside antibiotic that inhibits bacterial protein synthesis), **polymyxin B sulfate** (a polypeptide antibiotic that disrupts bacterial cell membranes), **hydrocortisone** (a corticosteroid that suppresses inflammation by regulating gene expression and protein synthesis), and **thonzonium bromide** (a surface-active agent that promotes penetration by dispersing cellular debris and exudate). It is primarily indicated for the treatment of infections and inflammation of the external ear canal, especially where the risk of bacterial infection and inflammation coexist. This formulation is **non-viscous, buffered at acidic pH**, instilled directly into the affected ear canal[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neomycin sulfate + polymyxin B sulfate + hydrocortisone + thonzonium bromide.